TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01147250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
Study: NCT00752934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral baclofen + placebo
Description: Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo + oral baclofen
Description: Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
Study: NCT02521870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(2)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(2)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(2)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101(2)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 7 weeks, then 9 weeks off, then dose Q1W for 4 weeks followed by dose Q3W for 7 weeks (up to 22 total doses).
Study: NCT00851292

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS probe
Description: end-firing and side-firing vary in the angle in which they sample the prostate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRUS probe
Description: end-firing and side-firing vary in the angle in which they sample the prostate
Study: NCT01951989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiglucérase (drug) pharmacokinetics
Study: NCT01335256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1000394
Description: BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
Study: NCT02521870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Study: NCT02332993

Intervention type: DIETARY_SUPPLEMENT
Intervention: FPP
Description: Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
Study: NCT01071499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.1 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.2 mg/kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One dose of morphine (0.3 mg/kg)
Study: NCT00372619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days
Study: NCT02292004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard ACL Reconstruction
Description: Standard surgical reconstruction of the ACL with autograft hamstring tendon
Study: NCT01268306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B+L Biotrue MPS and B+L PureVision
Description: Subjects use Bausch \& Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
Study: NCT02499159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivicaine
Description: 266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% standard bupivicaine
Description: standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
Study: NCT02438059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SoSu-liv website and app
Description: A 38 weeks web- and app-based tool for lifestyle changes intervention.
Study: NCT01532388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eScreen
Description: Web based self-monitoring of problematic alcohol and drug use.
Study: NCT00372619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Given IV for 5 days
Study: NCT02521870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SD-101(3)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SD-101(3)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SD-101(3)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SD-101(3)
Description: Dose Q1W for 4 weeks followed by dose Q3W for 16 additional weeks (up to 20 total doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses).
Study: NCT02288897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PV-10 (10% rose bengal disodium)
Study: NCT04755179

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy is performed according to daily practice but with the following standardized key points:~1. Conventional laparoscopy (three-trocar technique)~2. In case of purulent fluid: Suction and no peritoneal lavage procedure~3. Skelletizing of the mesoappendix (coagulation/clips according to routine practice locally)~4. Appendiceal stump closure: with two endoloops and dissected between the endoloops. In case of involvement of the appendiceal base, the use of endostapler is recommended.~5. Withdrawal of appendix: principle of abdominal wall protection is followed (trocar technique / endobag)~6. No drain placement, no nasogastric tube, and no urinary catheter routinely, only on indication.~7. Closure of wounds as appropriate

Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: Open appendectomy will be performed according to the following standardized key points:~1. Gridiron incision at the right lower quadrant. (McBurney's point)~2. After obtaining access to the abdominal cavity the principle of abdominal wall protection will be followed.~3. The appendiceal stump will be closed by ligation, not a purse string suture.~4. Closure of wounds as appropriate

Intervention type: PROCEDURE
Intervention: Non-operative treatment
Description: Non-operative treatment consisting of administration of intravenous antibiotics with or without drainage procedures (in case of an abscess), reserving an appendectomy for those not responding or with recurrent disease.~One of the two antibiotic regiments:~1. Combination A:~   1. Amoxicillin/clavulanic acid 25/2.5mg/kg 6 hourly (total 100/10 mg/kg daily. Maximum 6000/600mg a day) for children \<40 kg OR Amoxicillin/clavulanic acid 1000/200mg/kg 8 hourly (total 3000/6000 mg/kg daily) for children \> 40 kg~  2. Gentamicin 7mg/kg once daily~2. Combination B:~   1. Cefuroxim 25 mg/kg 6 hourly (total 100 mg/kg/day. Maximum 6gram/day)~  2. Metronidazole 10mg/kg 8hourly (total 30 mg/kg/day. Maximum 4000 mg/day) In case of peri-appendicular abscess the decision can be made to perform a drainage procedure either percutaneously or surgical.

Intervention type: PROCEDURE
Intervention: Direct appendectomy
Description: laparoscopic or open appendectomy as described
Study: NCT01105234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.
Study: NCT04425863

Intervention type: DRUG
Intervention: Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets
Description: 24 mg oral Ivermectin on days 0 and 7 and 1 Aspirin tablet daily for 30 days. Outpatient treatment.

Intervention type: OTHER
Intervention: Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets
Description: 36 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, 1 Aspirin tablet daily for 30 days. Inpatient treatment in ward care, including Low flow washed oxygen or oxygen concentrator

Intervention type: OTHER
Intervention: Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU.
Description: 48 mg oral Ivermectin on days 0 and 7; 1 daily injection of 4-mg Dexamethasone until discharge, Enoxaparin 100 IU/kg (ca. 1 mg/kg) daily until transfer to ward care. Then continue with inpatient treatment in ward care.
Study: NCT01728766

Intervention type: OTHER
Intervention: Small for gestational age at delivery
Description: Small for gestational age at delivery. gestational age at \>37 weeks by and birth weight \<2500 g
Study: NCT00372619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT00995631

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral lipectomy
Description: Standard (non-experimental) suction assisted liposuction surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral lipectomy
Description: Standard (non-experimental) suction assisted liposuction surgery
Study: NCT03484741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC and PRP
Description: MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
Study: NCT02297919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Effectiveness of Internet Based Obesity Control Programme
Study: NCT02288897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine, temozolomide or talimogene laherparepvec
Study: NCT02297919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of Internet Based Obesity Control Programme
Study: NCT03656211

Intervention type: OTHER
Intervention: Telephone interview
Description: Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview.
Study: NCT01728766

Intervention type: OTHER
Intervention: Post-term Infant, Not Heavy-for-dates
Description: Appropriate for gestational age at delivery. Gestational age at \>37 weeks and birth weight \>2800 g
Study: NCT00840385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAD
Description: Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
Study: NCT01312285

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resonator device
Description: low level magnetic fields

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resonator device
Description: low level magnetic fields
Study: NCT02253680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actico, short-stretch, inelastic dressing
Description: Worn 24hr post-operatively
Study: NCT04366739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHLORPROMAZINE (CPZ)
Description: Drug List 1, AMM obtained in 1952, AMM 3400930571187 1952/90, RCP revised 22/08/2019 Administration: oral route, if the clinical condition requires it, intravenous administration.~Initial dosage: 75 mg per day orally (or 37.5 mg per day orally in subjects 75 years of age or older).~Then: titration up to the maximum tolerated dose, with a minimum of 12.5 mg and a maximum of 300 mg per day by the oral administration (or 600 mg per day by the oral in certain exceptional cases which also correspond to the CPM CPM marketing authorization indications); or from 6.25 to 150 mg per day intravenously.~Duration of treatment: until healing criteria are obtained (≥ 8 days from the onset of COVID-19 symptoms AND ≥ 48 hours of apyrexia and absence of dyspnea) or 21 days maximum

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: In the absence of a reference treatment in COVID-19, the standard of care (SOC) is the comparison arm
Study: NCT02132689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actilyse (Thrombolytic therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparine (Standard anticoagulation therapy)
Study: NCT00372619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given intrathecally or IT age based dosage
Study: NCT02132689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparine (Standard anticoagulation therapy)
Study: NCT04484038

Intervention type: RADIATION
Group type: OTHER
Intervention: hypofractionated postoperative radiation therapy
Description: The patients included in the study will undergo intensity-modulated radiotherapy, of any modality, and image-guided (IGRT) with an emphasis on tissue preservation and administration precision through the use of devices that guarantee the stability and reproducibility of the same.
Study: NCT00939341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort (Budesonide/Formoterol)
Description: Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
Study: NCT04501965

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine/Azithromycine
Description: Dual treatment with Hydroxychloroquine and Azythromycin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Quinquina-Stevia/Azythromycin
Description: Dual treatment with Quinquina/Stevia (3/0,5) and Azythromycin

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 4Plants/Azythromycin
Description: Dual treatment with 4 plant species drug and Azythromycin
Study: NCT02455843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Patients assigned to the combination group will be treated with microwave in the primary tumor site

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microwave ablation
Description: Patients assigned to the combination group will be treated with microwave in the primary tumor site
Study: NCT01834638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: capsule(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: capsule(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: capsule(s)
Study: NCT02141529

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unipolar pulsed radiofrequency thermocoagulation
Description: Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar pulsed radiofrequency thermocoagulation
Description: Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
Study: NCT01408732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Description: 3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Description: 3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Normal standard of care followed by Drug interevention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Normal standard of care followed by Drug interevention
Study: NCT02844322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
Study: NCT02411773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate
Description: Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum bicarbonate \> 30).
Study: NCT03471130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 Low dose
Description: Oral, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-8554 High dose
Description: Oral, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral, 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral, 7 days